Commentary on: Prud'homme GJ, Glinka Y.Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 2012; 3:921-39. The recent article by Prud'homme et al [1] suggests that neuropilin-1 may contribute to tumor progression in a number of systemic malignancies and that it's down regulation may markedly decrease tumor growth. For instance, up regulation of neuropilin-1 levels results in a poor clinical outcome in tongue squamous cell carcinomas. Shorter overall survival is seen in oral tumors with NRP1/SEMA3A ratio greater than one [2] . Overall, invasiveness in these tumors is attenuated by knockdown of neuropilin-1. Neuropilin-1 knock-down is accompanied by attenuation of intra-tumoral vimentin levels [3] . A simultaneous increase in intra-tumoral Ecadherin levels is seen. Neuropilin-1 knockdown may be a potential therapeutic modality for treatment of tongue malignancies. Similarly, increased expression of neuropilin-1 is seen in breast carcinoma stem like cells. This accentuation of neuropilin-1 levels results in altered NF-κB activation and subsequent formation of tumor mammospheres [4] . Mammosphere formation is significantly attenuated by knock-down of neuropilin-1 by siRNA. Neuropilin-1 knock-down also results in decreased ERK1/2 phosphorylation. Thus neuropilin-1 may be a potential target for abrogation of tumor growth in breast carcinomas. Similarly, increased neuropilin-1 levels are seen in colorectal carcinomas. Agents such as miR320a abrogate the risk of developing hepatic metastasis in these tumors [5] . miR-320a mediates this effect by downregulating neuropilin-1 expression and the near future may see its increased use to attenuate the risk of liver metastasis from colorectal malignancies. Increased neuropilin-1 expression is also seen in pancreatic malignancies. The administration of sema3A-lytic hybrid peptide abrogates growth and progression in pancreatic malignancies by binding to neuropilin-1 [6]. Neuropilin-1 also promotes tumor growth in hepatocellular carcinomas by modulating vascular remodeling [7] .
The recent article by Prud'homme et al [1] suggests that neuropilin-1 may contribute to tumor progression in a number of systemic malignancies and that it's down regulation may markedly decrease tumor growth. For instance, up regulation of neuropilin-1 levels results in a poor clinical outcome in tongue squamous cell carcinomas. Shorter overall survival is seen in oral tumors with NRP1/SEMA3A ratio greater than one [2] . Overall, invasiveness in these tumors is attenuated by knockdown of neuropilin-1. Neuropilin-1 knock-down is accompanied by attenuation of intra-tumoral vimentin levels [3] . A simultaneous increase in intra-tumoral Ecadherin levels is seen. Neuropilin-1 knockdown may be a potential therapeutic modality for treatment of tongue malignancies. Similarly, increased expression of neuropilin-1 is seen in breast carcinoma stem like cells. This accentuation of neuropilin-1 levels results in altered NF-κB activation and subsequent formation of tumor mammospheres [4] . Mammosphere formation is significantly attenuated by knock-down of neuropilin-1 by siRNA. Neuropilin-1 knock-down also results in decreased ERK1/2 phosphorylation. Thus neuropilin-1 may be a potential target for abrogation of tumor growth in breast carcinomas. Similarly, increased neuropilin-1 levels are seen in colorectal carcinomas. Agents such as miR320a abrogate the risk of developing hepatic metastasis in these tumors [5] . miR-320a mediates this effect by downregulating neuropilin-1 expression and the near future may see its increased use to attenuate the risk of liver metastasis from colorectal malignancies. Increased neuropilin-1 expression is also seen in pancreatic malignancies. The administration of sema3A-lytic hybrid peptide abrogates growth and progression in pancreatic malignancies by binding to neuropilin-1 [6] . Neuropilin-1 also promotes tumor growth in hepatocellular carcinomas by modulating vascular remodeling [7] .
The above examples clearly illustrate the role of neuropilin-1 in tumor progression in systemic malignancies and the urgent need to identify further inhibitors of neuropilin-1 expression.
